Evidence map›Paper›PMID 33830997›Full record

ArticlePloS one2021

CaBagE: A Cas9-based Background Elimination strategy for targeted, long-read DNA sequencing.

Amelia D Wallace, Thomas A Sasani, Jordan Swanier, Brooke L Gates, Jeff Greenland, Brent S Pedersen, Katherine E Varley, Aaron R Quinlan

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Targeted sequencing ofmSystems · 2025
    Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Amelia D WallaceDepartment of Human Genetics, School of Medicine, University of Utah, Salt Lake City, Utah, United States of America.ORCID 0000-0001-9812-4236
Thomas A SasaniDepartment of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
Jordan SwanierDepartment of Human Genetics, School of Medicine, University of Utah, Salt Lake City, Utah, United States of America.
Brooke L GatesDepartment of Oncological Sciences, Huntsman Cancer Institute, Salt Lake City, Utah, United States of America.ORCID 0000-0001-9864-4012
Jeff GreenlandDepartment of Oncological Sciences, Huntsman Cancer Institute, Salt Lake City, Utah, United States of America.
Brent S PedersenDepartment of Human Genetics, School of Medicine, University of Utah, Salt Lake City, Utah, United States of America.
Katherine E VarleyDepartment of Oncological Sciences, Huntsman Cancer Institute, Salt Lake City, Utah, United States of America.
Aaron R QuinlanDepartment of Human Genetics, School of Medicine, University of Utah, Salt Lake City, Utah, United States of America.ORCID 0000-0003-1756-0859

Funding

TRAINING PROGRAM IN GENETICST32GM007464 · NIGMS · UNIVERSITY OF UTAH · PI GRUNWALD, DAVID J., STANFIELD, GILLIAN · 1985 to 2020
$6.1M
New algorithms and tools for large-scale genomic analysesR01HG006693 · NHGRI · UNIVERSITY OF VIRGINIA · PI QUINLAN, AARON R · 2012 to 2018
$3.1M
Training Program in Genomic MedicineT32HG008962 · NHGRI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Lynn Jorde, Aaron R Quinlan · 2016 to 2026
$3.0M
Software for exploring all forms of genetic variation in any speciesR01GM124355 · NIGMS · UNIVERSITY OF UTAH · PI QUINLAN, AARON R · 2017 to 2020
$1.8M
Genomics Summer Research for Minorities: A Pathway to Promote Diversity in Science ResearchR25HG009886 · NHGRI · UNIVERSITY OF UTAH · PI YOST, H. JOSEPH · 2018 to 2022
$1.3M
NHGRI NIH HHS R01 HG006693NHGRI NIH HHS R25 HG009886NHGRI NIH HHS T32 HG008962NIGMS NIH HHS R01 GM124355NIGMS NIH HHS T32 GM007464
6 · The paper itself

Abstract

A substantial fraction of the human genome is difficult to interrogate with short-read DNA sequencing technologies due to paralogy, complex haplotype structures, or tandem repeats. Long-read sequencing technologies, such as Oxford Nanopore's MinION, enable direct measurement of complex loci without introducing many of the biases inherent to short-read methods, though they suffer from relatively lower throughput. This limitation has motivated recent efforts to develop amplification-free strategies to target and enrich loci of interest for subsequent sequencing with long reads. Here, we present CaBagE, a method for target enrichment that is efficient and useful for sequencing large, structurally complex targets. The CaBagE method leverages the stable binding of Cas9 to its DNA target to protect desired fragments from digestion with exonuclease. Enriched DNA fragments are then sequenced with Oxford Nanopore's MinION long-read sequencing technology. Enrichment with CaBagE resulted in a median of 116X coverage (range 39-416) of target loci when tested on five genomic targets ranging from 4-20kb in length using healthy donor DNA. Four cancer gene targets were enriched in a single reaction and multiplexed on a single MinION flow cell. We further demonstrate the utility of CaBagE in two ALS patients with C9orf72 short tandem repeat expansions to produce genotype estimates commensurate with genotypes derived from repeat-primed PCR for each individual. With CaBagE there is a physical enrichment of on-target DNA in a given sample prior to sequencing. This feature allows adaptability across sequencing platforms and potential use as an enrichment strategy for applications beyond sequencing. CaBagE is a rapid enrichment method that can illuminate regions of the 'hidden genome' underlying human disease.

Indexed as

CRISPR-Cas SystemsDNA Repeat ExpansionGenome, HumanHigh-Throughput Nucleotide SequencingMicrosatellite RepeatsNanoporesAmyotrophic Lateral SclerosisC9orf72 ProteinHumansC9orf72 ProteinC9orf72 protein, human

Identifiers

PMID33830997
PMCPMC8031414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.